Abstract
A decline in forced expiratory volume (FEV1) is a hallmark of obstructive respiratory diseases, an important cause of morbidity among the elderly. While some data exist on biomarkers that are related to FEV1, we sought to do a systematic analysis of causal relations of biomarkers with FEV1.
Data from the general population-based AGES-Reykjavik study were used. Proteomic measurements were done using 4,782 DNA aptamers (SOMAmers). Data from 1,648 participants with spirometric data were used to assess the association of SOMAmer measurements with FEV1 using linear regression. Bi-directional Mendelian randomisation (MR) analyses were done to assess causal relations of observationally associated SOMAmers with FEV1, using genotype and SOMAmer data from 5,368 AGES-Reykjavik participants and genetic associations with FEV1 from a publicly available GWAS (n = 400,102).
In observational analyses, 473 SOMAmers were associated with FEV1 after multiple testing adjustment. The most significant were R-Spondin 4, Alkaline Phosphatase, Placental Like 2 and Retinoic Acid Receptor Responder 2. Of the 235 SOMAmers with genetic data, eight were associated with FEV1 in MR analyses. Three were directionally consistent with the observational estimate, Thrombospondin 2 (THBS2), Endoplasmic Reticulum Oxidoreductase 1 Beta and Apolipoprotein M. THBS2 was further supported by a colocalization analysis. Analyses in the reverse direction, testing whether changes in SOMAmer levels were caused by changes in FEV1, were performed but no significant associations were found after multiple testing adjustments.
In summary, this large scale proteogenomic analyses of FEV1 reveals protein markers of FEV1, as well as several proteins with potential causality to lung function.
Competing Interest Statement
The study was supported by the Novartis Institute for Biomedical Research, and protein measurements for the AGES-Reykjavik cohort were performed at SomaLogic. JJL, YJW. and LLJ are employees and stockholders of Novartis. GTA and GG report travel support from Boehringer-Ingelheim for work not related to the study. No other potential conflicts of interest relevant to this article were reported.
Funding Statement
The AGES-Reykjavik study was funded by Icelandic Heart Association, National Institute on Aging contract N01-AG-12100 and HHSN271201200022C, and Althingi (the Icelandic Parliament). GTA was supported by the Eimskip University Fund from the University of Iceland. GG was supported by the University of Iceland and by Landspitali University Hospital. TJ and VaG were supported by the University of Iceland, VaG by its postdoctoral fund. All protein measurements were funded by Novartis.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
AGES-Reykjavik was approved by the National Bioethics Committee in Iceland that acts as the Institutional Review Board for the Icelandic Heart Association (approval number: VSN-00-063), and by the National Institute on Aging Intramural Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding. The AGES-Reykjavik study was funded by Icelandic Heart Association, National Institute on Aging contract N01-AG-12100 and HHSN271201200022C, and Althingi (the Icelandic Parliament). GTA was supported by the Eimskip University Fund from the University of Iceland. GG was supported by the University of Iceland and by Landspitali University Hospital. TJ and VaG were supported by the University of Iceland, VaG by its postdoctoral fund. All protein measurements were funded by Novartis.
Competing interests: The study was supported by the Novartis Institute for Biomedical Research, and protein measurements for the AGES-Reykjavik cohort were performed at SomaLogic. JJL, YJW. and LLJ are employees and stockholders of Novartis. GTA and GG report travel support from Boehringer-Ingelheim for work not related to the study. No other potential conflicts of interest relevant to this article were reported.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
